News & Updates

In the treatment of patients with proliferative diabetic retinopathy, brolucizumab outperforms panretinal laser photocoagulation in terms of preserving visual acuity, according to the international phase III CONDOR trial.

Patients with noncentre point-involving geographic atrophy (GA) who receive avacincaptad pegol (ACP) 2 mg every month (EM) or every other month (EOM) show a persistent decrease in GA growth over 2 years relative to sham therapy, with no new safety signals, according to the GATHER2 study.